WuXi Biologics Congratulates Vir Biotechnology on Positive Data from Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
SHANGHAI, February 8, 2021 – WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, congratulates its partner Vir Biotechnology (Nasdaq: VIR) on initial topline data from the ongoing trial of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection.
VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and also to reduce the level of virions and subviral particles in the blood. Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients.
Through its integrated biologics technology platform, WuXi Biologics helped Vir address the technical challenges of Vir-3434 CMC development and successfully delivered clinical materials for an Investigational New Drug (IND) application and clinical trial. The partnership between Vir and WuXi Biologics has accelerated the timely delivery of new, investigational therapies for the treatment of a serious chronic infectious disease that affects millions of people worldwide.
“Extrapolating from our preclinical data, we expected it might require much higher doses of VIR-3434 to achieve this level of HBsAg knockdown. To have achieved it with a dose of 6 mg is unexpected.” said George A. Scangos, Ph.D., CEO of Vir Biotechnology. “The technical expertise and capabilities of the WuXi Biologics team have been important to our efforts to advance new therapies that have the potential to deliver a functional cure for HBV, and we appreciate their ongoing commitment to addressing patient needs.”
“Congratulations to Vir on this exciting progress,” said Dr. Chris Chen, CEO of WuXi Biologics, “We are honored to enable Vir to turn promising candidates into potential tangible treatments to fulfill the unmet medical needs in the field of infectious disease. WuXi Biologics will continue to deliver high quality biologics through our robust global supply chain network to expedite clinical development of this program to benefit patients worldwide.”
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly one-stop service offering and strong value proposition to its global clients. As of June 30, 2020, there were a total of 286 integrated projects, including 141 projects in pre-clinical development stage, 125 projects in early-phase (phase I and II) clinical development, 19 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 300,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.